DIA Global Annual Meeting 2025 Through Our Eyes: Lessons, Shifts, and Signals

What happens when the world’s sharpest regulatory minds gather under one roof? You get clarity in the chaos. DIA Global Annual Meeting 2025 didn’t just give us updates; this DIA conference gave us a front-row seat to the tectonic shifts shaping the future of Regulatory Affairs. From FDA policy shifts shaping the future of Regulatory Affairs and pharma regulatory intelligence, scaled AI adoption to cutting-edge innovations beyond traditional automation.

For those who couldn’t attend or couldn’t make every session, this is our take. Not a summary of agendas and speaker quotes, but the real undercurrents we sensed. Three transformative themes emerged, crucial for leaders aiming to thrive in this evolving environment. Let’s dive in.

The FDA Is Evolving and So Should We

Something felt different in the FDA conversations this year. Recent FDA developments, including a new commissioner, the discussions around global health authority collaboration, and accelerated adoption of artificial intelligence, indicate profound acknowledgement of the need for change. The shift to AI-driven processes highlights a critical need for regulatory professionals to become AI-literate, especially as AI in regulatory compliance and automated regulatory intelligence shape collaborative human-AI workflows.

But here’s the challenge and the opportunity: as the FDA becomes more tech-driven, it demands new skills. Not just from its own people, but from the industry. Regulatory professionals must now speak two languages: compliance and AI. And while this shift won’t rewrite filing strategies overnight, it may slow timelines, change review dynamics, and deepen the push toward specialized and dynamic regulatory agility. Interestingly, the industry is even still at a demand to find talent and expertise but with pressure to address cost. Consequently, there's growing demand for regulatory talent and increased reliance on automation solutions such as automated QC and automation in medical writing.

So, what should sponsor and regulatory teams do?

Build AI Literacy

Regulatory teams don’t need to code, but they must understand how AI works, what it outputs, and how to validate it.

Go Data-First

Address the data requirements of submissions to right size RIM data collection and establish governance in the creation and maintenance. Leveraging technology in the fix of data needs and creation of data, especially where standards are beginning to be applied, has immense potential.

Get Tech-Review Ready

Be prepared to explain and defend the AI tools you use, from validation to governance.

Rethink Organizational Design and Roles

Cost pressures and technology present opportunities to move roles into global operating locations and segment responsibilities where specialization is valued and processes can be automated.

It’s no longer enough to be submission ready. You need to be AI-intelligent

From Pilots to Production: The AI Hype is Over

The era of the AI pilot is matured. Each was an experiment, a proof of concept. But this year, that era has matured expecting concepts that are applied, focused, and outcomes driven.

A dominant theme at DIA Global Annual Meeting 2025 was the industry's shift from isolated pilots toward full-scale technology implementation. Critical success factors include:

Sponsors want partners that can solution and scale. They expect rigorous validation, not just enthusiasm. And they’re asking tough questions: How soon will this pay off? Can it scale? What’s the regulatory risk? What role will my people play in design and post deployment?

If you’re still stuck in sandbox mode, the message was loud and clear: it’s time to build real roads.

Scaling GenAI isn’t about more tech. It’s about embedding trust, governance, and usability into the everyday fabric of regulatory organizations. That trust doesn’t come easily. Regulatory teams are learning that AI validation isn’t a one-time task—it’s a continuous discipline. Every generated output must be traceable, reviewable, and ready for scrutiny. You can’t just plug in a model and hope it behaves. So, the question isn’t whether GenAI works, it’s whether it still works at scale.

Just as critical is the people side of the equation. Training, change fatigue, resistance from experienced teams. These were the real barriers to adoption. The shift to scaled GenAI is as much cultural as it is technical. The successful companies aren’t just building smarter tools—they’re building internal conviction and external confidence.

This shift didn’t happen overnight. Back in 2023, we explored the early promise of GenAI in Regulatory Affairs—its use cases, challenges, and practical applications—in our blog Applying Generative AI (like ChatGPT) in Regulatory Affairs: From Hype to Practical Applications. Since then, the conversation has matured. Today, it’s not about if GenAI works—it’s about how to scale it and prove its value.

Curious about what it actually takes to scale GenAI from pilots to enterprise-wide impact? Check out this blog: From Pilots to Impact: What it Really Takes to Scale GenAI in Pharma

Medical Writing Automation Is Just the Beginning

One of the liveliest conversations we had was about medical writing. Yes, automation in medical writing is saving time and resources, but that’s old news now.

This tension between acceleration and accountability was something we explored in more detail in a recent blog, Harnessing Content Intelligence for Medical Writers: Insights on Benefits and Risks, which takes a closer look at how automation intersects with medical writing judgment, and where the boundaries must be drawn.

But with all this tech, one message was clear: human oversight is not optional. Domain expertise, contextual judgment, ethical scrutiny can’t be delegated to AI. Not now. Maybe not ever.

Final Thoughts: It’s Not Just Change. It’s a New Era.

At DIA Global Annual Meeting 2025, the mood was unmistakable - this DIA Global gathering signalled that automated regulatory intelligence, automated QC, and automation in medical writing are not just trends but lasting shifts. This isn’t a phase of regulatory evolution, It’s a leap. From AI to talent shifts, from compliance pressures to innovation surges, the ground beneath our industry is moving fast. For us at Indegene, these takeaways aren’t just insights, they’re action items. We’re already embedding them into our solutions, services, and conversations with clients.

Let’s talk if you’re looking to move beyond pilots, build AI-ready regulatory teams, or simply make sense of what this new era means for your organization.